Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Wallach

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|September 7, 2025
Risk factors for brucellosis relapse and focal complications: A nine-year multicenter study in an endemic regionMaryam Dadar, Niloofar Sadooghi, Fereshteh Ansari, et al.
The Journal of Infectious Diseases|July 23, 2002
Diminished production of T helper 1 cytokines correlates with T cell unresponsiveness to Brucella cytoplasmic proteins in chronic human brucellosisGuillermo H Giambartolomei, M Victoria Delpino, Mariela E Cahanovich, et al.
Journal of Ultrasound in Medicine : Official Journal of the American Institute of Ultrasound in Medicine|March 31, 2019
Ultrasound and Histopathologic Correlation of Ovarian Cystadenofibromas: Diagnostic Value of the "Shadow Sign"Ilan E Timor-Tritsch, Esther Yoon, Ana Monteagudo, et al.
Cancer Treatment Reports|April 1, 1978
Treatment of advanced ovarian cancer with cis=dichlorodiammineplatinum(II): poor-risk patients with intensive prior therapyH W Bruckner, C J Cohen, R C Wallach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2004
Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology GroupHoward Hochster, Elizabeth R Plimack, Carolyn D Runowicz, et al.
Infection and Immunity|November 7, 2007
Brucella abortus inhibits major histocompatibility complex class II expression and antigen processing through interleukin-6 secretion via Toll-like receptor 2Paula Barrionuevo, Juliana Cassataro, M Victoria Delpino, et al.
American Journal of Obstetrics and Gynecology|July 1, 1986
Endocrine aspects of human uterine sarcoma: a preliminary studyL Tseng, J K Tseng, W J Mann, et al.
American Journal of Obstetrics and Gynecology|April 15, 1983
Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO Stages III and IV) as measured by surgical end-staging (second-look operation)C J Cohen, J D Goldberg, J F Holland, et al.
Cancer|May 1, 1981
Improved chemotherapy for ovarian cancer with cis-diamminedichloroplatinum and adriamycinH W Bruckner, C J Cohen, J D Goldberg, et al.
American Journal of Obstetrics and Gynecology|March 15, 1983
Cisplatin regimens and improved prognosis of patients with poorly differentiated ovarian cancerH W Bruckner, C J Cohen, J D Goldberg, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|September 7, 2025
Risk factors for brucellosis relapse and focal complications: A nine-year multicenter study in an endemic regionMaryam Dadar, Niloofar Sadooghi, Fereshteh Ansari, et al.
The Journal of Infectious Diseases|July 23, 2002
Diminished production of T helper 1 cytokines correlates with T cell unresponsiveness to Brucella cytoplasmic proteins in chronic human brucellosisGuillermo H Giambartolomei, M Victoria Delpino, Mariela E Cahanovich, et al.
Journal of Ultrasound in Medicine : Official Journal of the American Institute of Ultrasound in Medicine|March 31, 2019
Ultrasound and Histopathologic Correlation of Ovarian Cystadenofibromas: Diagnostic Value of the "Shadow Sign"Ilan E Timor-Tritsch, Esther Yoon, Ana Monteagudo, et al.
Cancer Treatment Reports|April 1, 1978
Treatment of advanced ovarian cancer with cis=dichlorodiammineplatinum(II): poor-risk patients with intensive prior therapyH W Bruckner, C J Cohen, R C Wallach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2004
Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology GroupHoward Hochster, Elizabeth R Plimack, Carolyn D Runowicz, et al.
Infection and Immunity|November 7, 2007
Brucella abortus inhibits major histocompatibility complex class II expression and antigen processing through interleukin-6 secretion via Toll-like receptor 2Paula Barrionuevo, Juliana Cassataro, M Victoria Delpino, et al.
American Journal of Obstetrics and Gynecology|July 1, 1986
Endocrine aspects of human uterine sarcoma: a preliminary studyL Tseng, J K Tseng, W J Mann, et al.
American Journal of Obstetrics and Gynecology|April 15, 1983
Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO Stages III and IV) as measured by surgical end-staging (second-look operation)C J Cohen, J D Goldberg, J F Holland, et al.
Cancer|May 1, 1981
Improved chemotherapy for ovarian cancer with cis-diamminedichloroplatinum and adriamycinH W Bruckner, C J Cohen, J D Goldberg, et al.
American Journal of Obstetrics and Gynecology|March 15, 1983
Cisplatin regimens and improved prognosis of patients with poorly differentiated ovarian cancerH W Bruckner, C J Cohen, J D Goldberg, et al.
Pageof 10